SPX 101

Drug Profile

SPX 101

Alternative Names: SPX-101

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator Spyryx Biosciences
  • Class Peptides
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 05 Apr 2017 Spyryx Biosciences plans a phase II trial for Cystic fibrosis in mid 2017
  • 05 Apr 2017 Additional pharmacodynamics data from a preclinical study in Cystic fibrosis released by Spyryx Biosciences
  • 28 Feb 2017 Adverse events and pharmacokinetics data from a phase I trial in Cystic fibrosis (In volunteers) released by Spyryx Biosciences (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top